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Abstract
Background: Herpes simplex virus type-2 is the common cause of genital ulcer disease worldwide. Genital herpes
infection is a major concern in pregnancy due to the risk of neonatal transmission.
Method: A Cross-sectional survey was conducted from December 2013 to September 2014 in randomly selected
28 health centers to assess the seroprevalence and risk factors of herpes simplex virus type-2 infection among
pregnant women attending antenatal care in Wolaita zone, Southern Ethiopia. After taking written consent socio
demographic, behavioral, obstetric history and family planning data along with blood samples were collected from
252 pregnant women using pre-structured questionnaire. Sera were tested using HerpeSelect-2 ELISA IgG. Data
entry and analysis was done using Epi info 3.5.4 and SPSS 21.00 respectively. Binary logistic regression was
performed to identify the risk factors associated with HSV-2 seropositivity. P-values less than 0.05 were considered
statistically significant.
Results: The overall seroprevalence of HSV-2 infection was 32.1 % (81/252) among pregnant women in Wolaita zone.
Independent predictors of HSV-2 infection includes daily laborer (AOR 1.293, 95 % CI: 1.033–1.739; p = 0.022), having
one sexual partners (AOR 0.476, 95 % CI: 0 .250 –0.904; p = 0.023), history of STDs (AOR 2.822, 95 % CI: 1.50–5.289;
p = 0.001) and use of contraceptive (AOR 2.602, 95 % CI: 1.407–4.812; p = 0.002).
Conclusion: Overall seroprevalence of HSV-2 infection among pregnant women of Wolaita Zone is high. Awareness
creation among high risk groups like women who have history of STD should be strengthened. Strengthening the
quality of health service delivery and expansion of health service coverage is mandatory.
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Background
Herpes simplex virus type 2 (HSV-2) is the leading cause
of genital ulcer diseases (GUD) worldwide. It is ubiquitous
DNA virus belonging to the family of Herpesviridae and it
is commonly found in the lumbosacral ganglia in the
latent phase [1, 2].
Sexually transmitted diseases (STDs) resulted in
stigma and social discrimination in young adult women
worldwide [3]. Though incidence of STDs is decreasing,
disease caused by HSV-2 infection is overwhelming.
Globally 417 million people aged 15–49 years living with
HSV-2 infection in 2012, of this 267 million were
women. From these infected women 19.2 million were
new cases [4]. Global prevalence was higher in women
compared to men, especially among young people [5].
In developing countries, it is uncommon to visit health
facilities unless having sign and symptom of disease.
Prevalence of HSV2 has been observed in higher rate in
Sub-Saharan Africa and it occurs more frequently in
women (30 to 50 %) than in men (10 to 50 %). More
than 80 % of female commercial sex workers were
infected with HSV-2 [6, 7].
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Neonatal herpes is devastating disease with a 20 %
overall mortality; more than 50 % of affected infants
have moderate or more severe neurological impairment.
Approximately 90 % of all neonatal herpes infections are
transmitted during delivery and at least 5 % transmitted
in utero. HSV-2 is implicated in more than half (55 %)
of neonatal herpes infections [8]. When primary HSV
infection occurs during late pregnancy there is not
adequate time to produce antibodies before give birth to
suppress viral replication. So that the risk of neonatal
infection varies from 30 to 50 % if infection is acquired
in the late pregnancy but it is around 1 % in the early
pregnancy [9].
Recurrent infection is the common character of HSV-2
infection. It favors HIV transmission by disrupting
the mucosal barrier and inflammatory changes, which
increases recruitment of HIV target cells to the ulcer.
Studies indicated that HIV acquisition increased 2 to 4
fold [10, 11]. HSV-2 prevalence is also higher among HIV-
infected women; study conducted in Central African
Republic showed that HSV-2 antibody prevalence is 91 %.
HIV co-infected pregnant women who have clinical
genital herpes during pregnancy increases the risk of HIV
infection to their infants [12].
HSV-2 infection can be contracted by having sex with
infected persons and vertically from mother to foetus/
neonates. The first time infection of the mother at third
trimester may lead foetus to severe illness and associated
with virus transmission from mother to foetus/newborn
because of lacking of preexisting antibody [1].
Infections caused by HSV-2 have a higher rate of reacti-
vation. Periodic reactivation from latency is possible and
leads to viral shedding from the site of the initial infection.
Antiviral therapy does not eradicate latent virus [13, 14].
Individuals infected with HSV-2 are usually asymp-
tomatic but able to transmit the virus to the new born
baby. Due to the risk of neonatal transmission assess-
ment of pregnant women sero status is indispensable to
treat mother and to make safe new born baby parallel.
In addition to that it helps to know the burden of HSV
type-2 infection.
The present study aimed to assess the sero preva-
lence of HSV-2 and associated risk factors among
pregnant women attending antenatal care (ANC) in
Wolaita zone, Southern Ethiopia, using type specific
HSV-2 antibody assay; its structural glycoprotein G
(gG-1 in HSV-1 and gG-2 in HSV-2) used to elicit
type-specific response [15].
Methods
Study area and population
The study was an institution based cross-sectional study
conducted from December 2013 to September 2014 in
selected health centers in Wolaita Zone, Ethiopia. A
total of 252 pregnant women attending antenatal clinics
(ANCs) in 28 health centers representing the general
population were enrolled in the study. Health centers
were stratified based on the place: urban and rural. Selec-
tion of health centers were made using simple random
sampling method; six from 15 urban health centers and 22
from 55 rural health centers proportionally. Systematically
nine study subjects were taken from each selected health
center; every seventh client from all pregnant women who
seek ANC in selected institution.
Data and specimen collection
Socio demographic, behavioral, obstetric history and
family planning data were collected using pre-structured
questionnaire from each participant. Aseptically 5 ml
blood was collected using BD Vacutainer blood collec-
tion tube.
Specimen processing
Blood samples were allowed to clot at room temperature
prior to centrifugation for 30 min. Serum was separated
and transferred to a tightly closing cryo tube vials for
storage at −20 °C until further processing. Serum speci-
mens were screened for HSV-2 infection using Herpe
Select 2 ELISA IgG test kit (Focus Diagnostics).
Focus Diagnostics’ HerpeSelect 2 ELISA IgG test kit
coated with recombinant gG-2 antigen (molecular
weight of 80 to 110 kilodaltons) was used for the
qualitative detection of human IgG class antibody to
HSV-2 [15].
Controls were used to monitor for substantial re-
agent failure. Vial of human serum with IgG used as
positive control which helps to assures reagent func-
tionality and vial of human serum without IgG used as
negative control.
Enzyme linked immune sorbent assay (ELISA)
One hundred milliliter diluted serum samples and
controls were incubated in the wells for 1 h at room
temperature after covering plates with sealing tape to
allow specific antibody present in the samples to react
with the antigen. Nonspecific reactants were removed
by washing 3× with wash buffer solution and 100 ml
peroxidase-conjugated anti-human IgG was added and
incubated for 30 min at room temperature. Excess
conjugate was removed by washing 3× with wash
buffer. 100 ml Enzyme substrate and chromogen was
added, and the color was allowed to develop by incu-
bating for 10 min at room temperature. After adding
100 ml Stop Reagent, the resultant color change was
quantified by a spectrophotometric reading of optical
density (OD) at a wavelength of 450 nm. Sample OD read-
ings were compared with reference cut-off OD readings to
determine results.
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The cut-off value used to determine a positive test on
this kit was greater than1.10. Index value “less than and
equal to 1.10 and greater than and equal to 0.9” were
considered as equivocal and index values below 0.9 were
considered as negative.
To ensure quality each plate run included the cut-off
calibrator and all three controls and the result was as
the following.
 The mean value for the cut-off calibrator wells was
0.411 OD units.
 The High Positive Control index value was 3.82.
 The Low Positive Control index value was 1.9.
 The Negative Control index value was 0.6.
Index values = Sample optical density/the mean of the
Cutoff Calibrator [15].
Data entry and analysis
Socio demographic and behavioral data entry and ana-
lysis was done using Epi info 3.5.4 and SPSS 21.00
version statistical software respectively. Multivariable
regression was used to adjust or control the possible
confounding factors and to identify risk factors of
HSV2 seroprevalence. The cut point for Statistical
significance was P < 0.05.
Ethical statement
The study was approved by Ethics and Review Committee
of Department of Microbiology, Immunology and Para-
sitology, School of Medicine Addis Ababa University
with protocol number 2/T/2013. Letter of support was
obtained from Wolaita Zone Health department. All
women who tested positive were communicated their
results with the attending health professional and
Acyclovir was given. Written consent was obtained
from study participants in order to collect different data
including biological specimen.
Results
Socio demographic characteristics and personal behavior
From all pregnant women who visited ANC during the
study period, 252 pregnant women provided the required
data and blood samples giving the response rate 100 %.
The mean age of the study participants was 24.15 years
(SD ± 4.93) and ranged from 15 to 40 years. Majority
170(67.4 %) of the study participants were aged between
20 and 29 years and were Christians 250 (99.2 %). Almost
all pregnant women 245(97.2 %) were married. Majority
of the study participants were from Wolaita ethnic group,
which accounts 221(87.7 %) (Table 1).
Almost half of the study participants 133(52.8 %)
started first sexual intercourse between age 15 and
19 years. From the study participants, 96(38.1 %) had
Table 1 Distribution of ANC attendants by socio demographic
and personal behavior variables in Wolaita zone health centers,
SNNPR, Ethiopia, 2014
Variables HSV-2 sero status Total (%)
Negative (%) Positive (%)
Age
15–19 23(9.1) 17(6.7) 40(15.9)
20–24 65(25.8) 21(8.3) 86 (34.1)
25–29 54(21.4) 30(11.9) 84(33.3)
> =30 29(11.5) 13(5.2) 42(16.7)
Religion
Orthodox 51(20.2) 23(9.1) 74(29.4)




Married 166(65.9) 79(31.3) 245(97.2)




Wolaita 151(59.9) 70(27.8) 221(87.7)
Gurage 6(2.4) 2(0.8) 8(3.2)
Kenbata 1(0.4) 2(0.8) 3(1.2)
Hadya 1(0.4) 0 1(0.4)
Amara 4(1.6) 4(1.6) 8(3.2)
Oromo 3(1.2) 0 3(1.2)
Tigre 5(2) 3(1.2) 8(3.2)
Occupation
Gov. employee 17(6.7) 10(4) 27(10.7)
House wife 98(38.9) 44(17.5) 142(56.3)
Merchant 21(8.3) 18(7.1) 39(15.5)
Daily laborer 35(13.9) 9(3.6) 44(17.5)
Educational status
Illiterate 22(8.7) 9(3.6) 31(12.3)
Grade 1–4 27(10.7) 15(6) 42(16.7)
Grade 5–8 45(17.9) 24(9.5) 69(27.4)
Grade 9–12 49(19.4) 15(6) 64(25.4)
Above Grade 12 28(11.1) 18(7.1) 46(18.3)
Alcohol consumption
No 158(62.7) 73(29) 231(91.7)
Yes 13(5.2) 8(3.2) 21(8.3)
Cigarette smoking
No 170(67.5) 81(32.1) 251(99.6)
Yes 1(0.4) 1(0.4)
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two or more sexual partners throughout their lifetimes.
Five (2 %) of total population had sex with two or more
sexual partners in the last 6 months and had new or
non-steady sexual partners. One hundred and forty one
(56 %) study participants had history of STD. Among
the study participants, only 21 (8.3 %) and 1(0.4 %)
consume alcohol and smoke cigarette respectively.
During the study period, 89(35.3 %) study participants
got Provider Initiated Testing and Counseling service
(PITC) and 1(1.1 %) was positive for HIV (Table 1).
Obstetric history and family planning
In terms of obstetric history, majority of the study partici-
pants 187(74.2 %) were at age greater than or equal to
18 years at first pregnancy and the rest were less than
18 years. From all study participants, majority 145(57.5 %)
had more than three children. The median gestation week
of the participants was 28 weeks and ranged from 4 to
40 weeks (SD ± 7.775), majority of study subjects,
141(56 %) had 20–28 weeks gestational period.
Among all study participants, only 30(11.9 %) had
history of abortion. With regard to contraceptive, 141
(56 %) had been using contraceptive before being
pregnant. In the present study, HSV-2 was high among
pregnant women whose age were greater than or equal
to 18 years at first pregnancy, mother having “no birth-2”
children, gestational weeks between 20 and 28 weeks,
women who had no history of abortion and used
contraceptive which accounts 54(66.6), 38(46.9),44(54.3),
71(87.6) and 59(72.8 %) respectively (Table 2).
HSV-2 seroprevalence and risk factors
The overall seroprevalence of HSV-2 infection in Wolaita
Zone, Ethiopia was 32.1 % (81/252) among pregnant
women. Independent predictors of HSV-2 infection
includes daily laborer (AOR 1.293, 95 % CI: 1.033–
1.739; p = 0.022), having one sexual partners (AOR
0.476, 95 % CI: 0 .250 –0.904; p = 0.023), history of
STDs (AOR 2.822, 95 % CI: 1.50–5.289; p = 0.001)
and use of contraceptive (AOR 2.602, 95 % CI:
1.407–4.812; p = 0.002), these variables were used to
form multivariable logistic regression analysis
(Table 3). The cut point for Statistical significance
was P < 0.05.
Multivariable logistic regression analysis revealed
that daily laborers were 1.29 times likely to be posi-
tive for HSV-2 than merchants (P = 0.022, AOR 0.293,
95 % CI: 0.103–0.839), and having one sexual part-
ners were 52.4 % less likely to be positive than having
two or more sexual partner (p = 0.023, AOR0.476,
95 % CI: 0 .250 –0.904).
The seroprevalence of HSV-2 was 2.8 times higher
among Women who had a history of STD (p = 0.001,
AOR 2.822, 95 % CI: 1.50–5.289) and in contracep-
tive users it was 2.6 times high (p = 0.002, AOR
2.602, 95 % CI: 1.407–4.812). However, the associ-
ation of age at first sex disappeared in the multivariate
analysis (Table 4).
Table 1 Distribution of ANC attendants by socio demographic
and personal behavior variables in Wolaita zone health centers,
SNNPR, Ethiopia, 2014 (Continued)
Age at first sex. Intercourse
15–19 83(32.9) 50(19.8) 133(52.8)
20–24 82(32.5) 25(9.9) 107(42.5)
25–29 6(2.4) 6(2.4) 12(4.8)
Life time No of sex. Partners
1 94(37.3) 62(24.6) 156(61.9)
> =2 77(30.6) 19(7.5) 96(38.1)
Sex partner now
No 4(1.6) 3(1.2) 7(2.8)
Yes, regular 165(65.5) 76(30.2) 241(95.6)
Yes, occasional 2(0.8) 2(0.8) 4(1.6)
No of sex. partner last 6 month
1 167(66.3) 80(31.7) 247(98)
> =2 4(1.6) 1(0.4) 5(2)
History of STD
Yes 82(32.5) 59(23.4) 141(56)
No 89(35.3) 22(8.7) 111(44)
Table 2 Distribution of ANC attendants by Obstetric history
and family planning in Wolaita Zone health centers, SNNPR,
Ethiopia, 2014
Variables HSV-2 sero status Total (%)
Negative (%) Positive (%)
Age at 1st pregnancy
< 18 38(15.1) 27(10.7) 65(25.8)
> =18 133(52.8) 54(21.4) 187(74.2)
No of child
0–2 69(27.4) 38(15.1) 107(42.5)
3–5 65(25.8) 23(9.1) 88(34.9)
> 5 37(14.7) 20(7.9) 57(22.6)
Gestational wks
< 20 9(3.6) 6(2.4) 15(6)
20–28 97(38.5) 44(17.5) 141(56)
> 28 65(25.8) 31(12.3) 96(38.1)
Abortion
Yes 20(7.9) 10(4) 30(11.9)
No 151(59.9) 71(28.2) 222(88.1)
Used contraceptive
Yes 82(32.5) 59(23.4) 141(56)
No 89(35.3) 22(8.7) 111(44)
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Table 3 Bi variable models of factors associated with HSV-2 prevalence among pregnant women attending ANC in Wolaita zone
health centers, SNNPR, Ethiopia, 2014
Variables HSV-2 sero status COR 95 % C.I. for COR P- value
Negative (%) Positive (%) Lower Upper
Age
> =30 year 29(11.5) 13(5.2) 1
15–19 years 23(9.1) 17(6.7) 1.649 0.666 4.080 0.279
20–24 years 65(25.8) 21(8.3) 0.721 0.318 1.634 0.433
25–29 years 54(21.4) 30(11.9) 1.239 0.561 2.736 0.595
Educational level
Above grade 12 28(11.1) 18(7.1) 1
Illiterate 22(8.7) 9(3.6) 0.636 0.240 1.688 0.364
Grade 1–4 27(10.7) 15(6) 0.864 0.364 2.053 0.741
Grade 5–8 45(17.9) 24(9.5) 0.830 0.383 1.795 0.635
Grade 9–12 49(19.4) 15(6) 0.476 0.208 1.090 0.079
Occupation
Merchant 21(8.3) 18(7.1) 1
Gov.employee 17(6.7) 10(4) 0.686 0.252 1.872 0.462
Housewife 98(38.9) 44(17.5) 0.524 0.254 1.079 0.080
aDaily labours 35(13.9) 9(3.6) 2.410 1.114 3.788 0.015
1st sexual intercourse age
a25-29 years 6(2.4) 6(2.4) 1 0.028
15–19 years 83(32.9) 50(19.8) 0.602 0.184 1.970 0.402
20–24 years 82(32.5) 25(9.9) 0.305 0.090 1.030 0.056
Life time no of sex. partner
1 94(37.3) 62(24.6) 0.374 0.206 0.679 0.001
a > =2 77(30.6) 19(7.5) 1
STI symptoms
no 89(35.3) 22(8.7) 1
a yes 82(32.5) 59(23.4) 2.911 1.639 5.169 0.000
Gestation wks
> 28 weeks 65(25.8) 31(12.3) 1
< 20 week 9(3.6) 6(2.4) 1.398 0.457 4.276 0.557
20–28weeks 97(38.5) 44(17.5) 0.951 0.545 1.660 0.860
Age at 1st pregnancy
> =18 years 133(52.8) 54(21.4) 1
< 18 years 38(15.1) 27(10.7) 1.750 0.974 3.144 0.061
Contraceptive
No 89(35.3) 22(8.7) 1
a Yes 82(32.5) 59(23.4) 2.911 1.639 5.169 0.000
No of child
> 5 37(14.7) 20(7.9) 1
0-2 69(27.4) 38(15.1) 1.019 0.520 1.997 0.957
3–5 65(25.8) 23(9.1) 0.655 0.318 1.348 0.250
aStatistical significant association
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Discussion
In this study we found that 32.1 % (81/252) overall sero
prevalence of HSV-2 among pregnant women attending
antenatal care; which was higher as compared to studies
done in a similar study population in different coun-
tries, in USA 22 %, 7.6 % in Italy,14.5 % in Australia,
8.7 % in Northeast India and 20.7 % in a rural area
of Tanzania [16–20].
The higher prevalence in our study might be due to
various factors. First, the prevalence of HSV-2 might be
high among the general population especially in men.
Financial constraints might be the second factor as it
was difficult to cover screening cost in our country and
simultaneously creating awareness. For example, there
were no laboratory materials in the health centers to screen
HSV-2 in our country. Educational status might be the
other factor where majority of women in reference coun-
tries had better educational status than in Ethiopia. Place of
residence might have also played an important role. The
present study was done in southern part of Ethiopia where
we included many health centers from rural areas. The
areas had poor health facility, lack of transportation to
health facility and lack of health information might play
important role to increase the prevalence.
But the prevalence was lower from a study done in
Zimbabwe amongst women of childbearing age at high
risk group, which was 49.1 % [21]. This difference could
be due to the difference in the study group where we were
not focused only on high risk group. However, the study
done in Zimbabwe encompassed high risk group women.
Daily laborers had higher HSV-2 prevalence, and they
were 1.293 times more likely to be positive than
Merchant. This is in line with a study done in different
countries [22, 23]. This might be due to the fact that
women were working in high risk settings, like selling
coffee, tea and bread on the street, and waitress in bars
and this working environment might increase the risk to
exposure to multiple sexual partners.
Significant association was observed in the crude
analysis among participants who started first sexual
intercourse between age 25–29 years (p = 0.028). How-
ever, this association was lost in the multivariate analysis
after controlling occupation, life time number of sexual
partner, STI symptoms and contraceptive use.
Significant increase for the risk of acquiring HSV-2
infection was observed for women who had multiple
sexual partners, compared with women who had single
sexual partner (P = 0.001). It was similar with many
studies conducted in Zimbabwe, USA, North East India
and Tanzania [2, 19–21]. This might be due to increased
frequency of exposure to risky sexual intercourse.
When we see history of STD, strong association
was observed among participants who had STI
symptoms, compared with women who mentioned
never encountered STI symptoms (p = 0.00). This is
similar with a study conducted in Mexico which
showed significant associations in the crude analysis
among participants who had gonorrhea (OR = 1.7,
95 % CI: 1.1–3.0) and those individuals who tested
positive for exposure to T. pallidum (OR = 2.8, 95 %
Table 4 Multivariable models of factors associated with HSV-2 prevalence among pregnant women attending ANC in Wolaita zone
health centers, SNNPR, Ethiopia, 2014
Variables HSV-2 sero status AOR 95 % C.I. for AOR P-value
Negative (%) Positive (%) Lower Upper
Occupation
Merchant 21(8.3) 18(7.1) 1
Gov. employee 17(6.7) 10(4) 0.686 0.209 2.254 0.535
Housewife 98(38.9) 44(17.5) 0.593 0.262 1.341 0.210
aDaily labours 35(13.9) 9(3.6) 1.293 1.033 1.739 0.022
1st sexual intercourse age
25–29 years 6(2.4) 6(2.4) 1
15–19 years 83(32.9) 50(19.8) 0.704 0.170 2.917 0.628
20–24 years 82(32.5) 25(9.9) 0.339 0.080 1.433 0.141
Life time no of sex. partner
a1 94(37.3) 62(24.6) 0.476 0.250 0.904 0.023
STI symptoms
ayes 82(32.5) 59(23.4) 2.822 1.50 5.289 0.001
Contraceptive
ayes 82(32.5) 59(23.4) 2.602 1.407 4.812 0.002
aStatistical significant association
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CI: 1.7–5.0) [23]. This might be due to disrupted
mucosal barrier and inflammatory change.
When we see the association between HSV-2 and
hormonal contraceptive users, women who ever used
hormonal contraceptive in their life time had strong
association with the risk of acquiring HSV-2, compared
with never used contraceptive before (p = 0.000).It is the
same with a study in Mozambique, Beira where hormo-
nal contraceptive users had higher risk in acquiring
HSV-2 AOR 1.92 (CI: 1.16–3.19, P = 0.012) [24]. This
might be because of either they have had sex frequently
with infected individuals or immune suppression. Cell-
mediated immunity, which is important for control of
viral infections, is depressed by both estrogen and Dur-
ing pregnancy, serum estradiol and progesterone con-
centrations increase steadily, ultimately reaching levels
that are 10 to 100 fold higher than those occurring
during normal menstrual cycling [25].
The present study confirmed that HSV-2 prevalence
among pregnant women attending antenatal care in
Wolaita zone health center was high and this might
increase risk of neonatal transmission. A study in Italian
pregnant women showed that 3 % women acquired HSV
infection during pregnancy. In USA 2 % pregnant
women and 2.6 % in Norway acquired the infection close
to term and placing their newborn at risk for herpes
infection during delivery. The risk of infection varies
from 30 to 50 % during late pregnancy however it is 1 %
in early pregnancy [9, 26, 27].
Conclusion and recommendation
In the present study the Sero-prevalence of HSV-2
among pregnant women was high. Being daily laborer,
having two or more sexual partners, history of STD and
using hormonal contraceptive were independent predic-
tors for HSV-2 sero-prevalence. The risk of neonatal
transmission could be high because of high sero-
prevalence among pregnant women. Women who have
history of STD should be tested and treated early.
Health campaigns among women should promote
condom use; bring behavioral change and introduction
of STI screening. Strengthen the quality of health
service delivery and expand health service coverage. To
access STD clinics minister of health needs to work
without any reservation.
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